All In Biotech

Investigational drug · Phase 2

CRC01

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL).

Phase 2

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

4

Any phase or sponsor naming "CRC01"

First trial start

2021

Mar 2, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CRC01", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Relapsed Large B-cell Lymphoma
  • Refractory Large B-cell Lymphoma
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
  • High-grade B-cell Lymphoma
  • Transformed Follicular Lymphoma (TFL)
  • ALL (Acute B-Lymphoblastic Leukemia)
  • Lupus Nephritis
  • Lupus Nephritis (LN)
  • SLE

Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Lupus (SLE) · Hematology and blood cancers · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "CRC01" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 11 on PubMed

Also in development for Relapsed Large B-cell Lymphoma

  • TC011Phase 21 trial

    TICAROS Co., Ltd. · Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.